Continuous administration of dopa decarboxylase inhibitors and compositions for same

Patent metadata

Field	Value
Publication number	US-9993451-B2
Application number	US-201514789214-A
Country	US
Kind code	B2
Filing date	Jul 1, 2015
Priority date	May 19, 2009
Publication date	Jun 12, 2018
Grant date	Jun 12, 2018

Abstract

Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon monoxide or manganese intoxication, using substantially continuous administration of carbidopa or salt thereof together with administration of levodopa.

First claim

The invention claimed is:

1. A pharmaceutically acceptable liquid composition comprising levodopa, arginine, and about 0.5% to about 4% by weight carbidopa, wherein the pH of the liquid composition is about 8 to about 10 at 25° C.

2. The pharmaceutically acceptable liquid composition of claim 1 , wherein the pH is about 9.5 at 25° C.

3. The pharmaceutically acceptable liquid composition of claim 2 , comprising about 6% by weight levodopa.

4. The pharmaceutically acceptable liquid composition of claim 3 , comprising about 1 to about 20% by weight arginine.

5. The pharmaceutically acceptable liquid composition of claim 4 , further comprising N-acetyl cysteine.

6. The pharmaceutically acceptable liquid composition of claim 5 , further comprising ascorbic acid.

7. The pharmaceutically acceptable liquid composition of claim 6 , wherein the liquid composition has no precipitation when held for 48 hours at room temperature.

8. A method of treating a disease or disorder characterized by reduced levels of dopamine in a patient's brain, comprising administering to said patient an amount of a composition of claim 1 in an amount effective to treat said disease or disorder.

9. The method of claim 8 , wherein said administering is subcutaneous, transdermal, intradermal, intravenous, oral, intraduodenal, intramuscular, and/or direct absorption through mucous membrane tissues.

10. The method of claim 8 , wherein said administration is continuous.

11. The method of claim 8 , wherein said disease or disorder is Parkinson's disease or secondary parkinsonism.

12. The method of claim 8 , wherein said disease is Parkinson's disease.

13. The method of claim 9 , wherein said administering is continuous.

14. The method of claim 10 , wherein said administering is subcutaneous.

15. An infusion pump comprising the composition of claim 1 .

Assignees

• Neuroderm Ltd

Inventors

• Yacoby-Zeevi Oron
• Nemas Mara

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title